References
- Yung YC, Stoddard NC, Chun J. LPA receptor signaling: Pharmacology, physiology, and pathophysiology. J Lipid Res. 2014;55:1192–1214.
- Aikawa S, Hashimoto T, Kano K, et al. Lysophosphatidic acid as a lipid mediator with multiple biological actions. J Biochem. 2015;157:81–89.
- Stoddard NC, Chun J. Promising pharmacological directions in the world of lysophosphatidic acid signaling. Biomol Ther. 2015;23:1–11.
- Aoki J, Inoue A, Okudaira S. Two pathways for lysophosphatidic acid production. Biochim Biophys Acta. 2008;1781:513–518.
- Xu Y, Gaudette DC, Boynton JD, et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res. 1995;1:1223–1232.
- Yamada T, Furukawa M, Hotta M, et al. Mutations of lysophosphatidic acid receptor-1 gene during progression of lung tumors in rats. Biochem Biophys Res Commun. 2009;378:424–427.
- Obo Y, Yamada T, Furukawa M, et al. Frequent mutations of lysophosphatidic acid receptor-1 gene in rat liver tumors. Mutat Res. 2009;660:47–50.
- Tsujino M, Fujii M, Okabe K, et al. Differential expressions and DNA methylation patterns of lysophosphatidic acid receptor genes in human colon cancer cells. Virchows Arch. 2010;457:669–676.
- Tsujiuchi T, Hirane M, Dong Y, et al. Diverse effects of LPA receptors on cell motile activities of cancer cells. J Recept Signal Transduct Res. 2014;34:201–204.
- Sahai E. Illuminating the metastatic process. Nat Rev Cancer. 2007;7:737–749.
- Fukushima K, Takahashi K, Yamasaki E, et al. Lysophosphatidic acid signaling via LPA1 and LPA3 regulates cellular functions during tumor progression in pancreatic cancer cells. Exp Cell Res. 2017;352:139–145.
- Ishii S, Hirane M, Fukushima K, et al. Diverse effects of LPA4, LPA5 and LPA6 on the activation of tumor progression in pancreatic cancer cells. Biochem Biophys Res Commun. 2015;461:59–64.
- Komachi M, Tomura H, Malchinkhuu E, et al. LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites. Carcinogenesis. 2009;30:457–465.
- Takahashi K, Fukushima K, Tanaka K, et al. Involvement of LPA signaling via LPA receptor-2 in the promotion of malignant properties in osteosarcoma cells. Exp Cell Res. 2018;369:316–324.
- Ding Q, Yoshimitsu M, Kuwahata T, et al. Establishment of a highly migratory subclone reveals that CD133 contributes to migration and invasion through epithelial-mesenchymal transition in pancreatic cancer. Human Cell. 2012;25:1–8.
- Takahashi K, Fukushima K, Onishi Y, et al. Involvement of FFA1 and FFA4 in the regulation of cellular functions during tumor progression in colon cancer cells. Exp Cell Res. 2018;369:54–60.
- Kenakin T. Inverse, protean, and ligand-selective agonism: Matters of receptor conformation. Faseb J. 2001;15:598–611.
- Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell. 2010;141:52–67.
- Fischer DJ, Nusser N, Virag T, et al. Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol. Pharmacol. 2001;60:776–784.
- Samadi N, Bekele R, Capatos D, et al. Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance. Biochimie. 2011;93:61–70.
- Leblanc R, Peyruchaud O. New insights into the autotaxin/LPA axis in cancer development and metastasis. Exp Cell Res. 2015;333:183–189.
- Gierse J, Thorarensen A, Beltey K, et al. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. J Pharmacol Exp Ther. 2010;334:310–317.